Development of a Computerised Antithrombotic Risk Assessment Tool (CARAT) to optimise therapy in older persons with atrial fibrillation

被引:13
作者
Bajorek, Beata V. [1 ,2 ]
Masood, Noman [3 ]
Krass, Ines [4 ]
机构
[1] Univ Technol Sydney, Grad Sch Pharm, Sydney, NSW 2007, Australia
[2] Royal N Shore Hosp, Sydney, NSW, Australia
[3] Wyong Hosp, Dept Pharm, Kanwal, NSW, Australia
[4] Univ Sydney, Fac Pharm A15, Sydney, NSW 2006, Australia
关键词
antithrombotic; atrial fibrillation; decision support; elderly; risk assessment; stroke prevention; CLINICAL CLASSIFICATION SCHEMES; STROKE PREVENTION; PHYSICIAN ATTITUDES; NATIONAL REGISTRY; ANTICOAGULATION; WARFARIN; HEMORRHAGE; MANAGEMENT; IMPACT; AGE;
D O I
10.1111/j.1741-6612.2011.00546.x
中图分类号
R592 [老年病学]; C [社会科学总论];
学科分类号
03 ; 0303 ; 100203 ;
摘要
Aim: To develop and evaluate a novel Computerised Antithrombotic Risk Assessment Tool (CARAT) to aid clinicians' decision making regarding the riskbenefit of antithrombotic therapy in older patients. Methods: CARAT was developed in an iterative process involving multidisciplinary feedback and computerisation of previously trialled algorithms. Hospital-based clinicians then applied the tool to patient cases, to evaluate its usability. Results: Overall, 94% of clinicians (n= 27 yielding 216 responses) were satisfied with CARAT's format. Most (72%) clinician responses agreed with CARAT recommendations; over two-thirds agreed with estimates of stroke and bleeding risk. However, geriatricians were 3.5 times more likely to disagree with CARAT recommendations than cardiologists, particularly in cases of high fall risk. Overall, 63% responded that CARAT was at least somewhat useful for clinical practice; 22% indicating it was very useful. Conclusion: CARAT has potential as a useful decision-support tool to assist clinicians in decision making regarding appropriate antithrombotic therapy in older patients.
引用
收藏
页码:102 / 109
页数:8
相关论文
共 28 条
[1]  
[Anonymous], 2003, EV PRACT GAPS REP, V1
[2]   The impact of age on antithrombotic use in elderly patients with non-valvular atrial fibrillation [J].
Bajorek, B. V. ;
Krass, I. ;
Ogle, S. J. ;
Duguid, M. J. ;
Shenfield, G. M. .
AUSTRALASIAN JOURNAL ON AGEING, 2002, 21 (01) :36-41
[3]   Management of warfarin in atrial fibrillation: views of health professionals, older patients and their carers [J].
Bajorek, Beata V. ;
Ogle, Susan J. ;
Duguid, Margaret J. ;
Shenfield, Gillian M. ;
Krass, Ines .
MEDICAL JOURNAL OF AUSTRALIA, 2007, 186 (04) :175-180
[4]   Optimizing the use of antithrombotic therapy for atrial fibrillation in older people: A pharmacist-led multidisciplinary intervention [J].
Bajorek, BV ;
Krass, I ;
Ogle, SJ ;
Duguid, MJ ;
Shenfield, GM .
JOURNAL OF THE AMERICAN GERIATRICS SOCIETY, 2005, 53 (11) :1912-1920
[5]   PHYSICIAN VARIATION IN ANTICOAGULATING PATIENTS WITH ATRIAL-FIBRILLATION [J].
CHANG, HJ ;
BELL, JR ;
DEROO, DB ;
KIRK, JW ;
WASSON, JH .
ARCHIVES OF INTERNAL MEDICINE, 1990, 150 (01) :83-86
[6]   Warfarin prescribing in atrial fibrillation: The impact of physician, patient, and hospital characteristics [J].
Choudhry, Niteesh K. ;
Soumerai, Stephen B. ;
Normand, Sharon-Lise T. ;
Ross-Degnan, Dennis ;
Laupacis, Andreas ;
Anderson, Geoffrey M. .
AMERICAN JOURNAL OF MEDICINE, 2006, 119 (07) :607-615
[7]  
CMPMedica Australia Pty Ltd, HEART DIS RISK ASS
[8]  
Elliott R, 1999, PHARM J, V263, pR10
[9]   Age and the risk of warfarin-associated hemorrhage: The anticoagulation and risk factors in atrial fibrillation study [J].
Fang, Margaret C. ;
Go, Alan S. ;
Hylek, Elaine M. ;
Chang, Yuchiao ;
Henault, Lori E. ;
Jensvold, Nancy G. ;
Singer, Daniel E. .
JOURNAL OF THE AMERICAN GERIATRICS SOCIETY, 2006, 54 (08) :1231-1236
[10]  
Finsterer J, 2008, NETH J MED, V66, P327